Overview Dividends

(BSX) Boston Scientific - Ratings and Ratios

Exchange: NYSE • Country: United States • Currency: USD • Type: Common Stock • ISIN: US1011371077

Stents, Catheters, Pacemakers, Defibrillators, Lasers

EPS (Earnings per Share)

EPS (Earnings per Share) of BSX over the last years for every Quarter: "2020-09": 0.37, "2020-12": 0.23, "2021-03": 0.37, "2021-06": 0.4, "2021-09": 0.41, "2021-12": 0.45, "2022-03": 0.39, "2022-06": 0.44, "2022-09": 0.43, "2022-12": 0.49, "2023-03": 0.47, "2023-06": 0.53, "2023-09": 0.5, "2023-12": 0.55, "2024-03": 0.56, "2024-06": 0.62, "2024-09": 0.63, "2024-12": 0.7, "2025-03": 0.75, "2025-06": 0.75, "2025-09": 0.75,
EPS CAGR: 16.74%
EPS Trend: 97.1%
Last SUE: 2.12σ
Qual. Beats: 11

Revenue

Revenue of BSX over the last years for every Quarter: 2020-09: 2659, 2020-12: 2708, 2021-03: 2752, 2021-06: 3077, 2021-09: 2932, 2021-12: 3127, 2022-03: 3026, 2022-06: 3244, 2022-09: 3170, 2022-12: 3242, 2023-03: 3389, 2023-06: 3599, 2023-09: 3527, 2023-12: 3725, 2024-03: 3856, 2024-06: 4120, 2024-09: 4209, 2024-12: 4561, 2025-03: 4663, 2025-06: 5061, 2025-09: 5065,
Revenue CAGR: 17.61%
Revenue Trend: 99.0%
Last SUE: 2.10σ
Qual. Beats: 8
Risk via 10d forecast
Volatility 23.2%
Value at Risk 5%th 35.3%
Relative Tail Risk -7.62%
Reward TTM
Sharpe Ratio 0.25
Alpha -3.02
Character TTM
Hurst Exponent 0.534
Beta 0.690
Beta Downside 0.874
Drawdowns 3y
Max DD 15.52%
Mean DD 2.71%
Median DD 1.72%

Description: BSX Boston Scientific September 25, 2025

Boston Scientific Corp (NYSE:BSX) designs, manufactures, and markets a broad range of medical devices across two primary segments-MedSurg and Cardiovascular-serving interventional specialties worldwide. The firm, founded in 1979 and based in Marlborough, Massachusetts, leverages a diversified product slate that spans gastrointestinal, urological, neurological, and cardiac therapies.

Within MedSurg, the company offers gastrointestinal tools (e.g., resolution clips, biliary stents, single-use duodenoscopes), urology solutions (ureteral stents, digital flexible ureteroscopes, holmium lasers, penile implants), and neuromodulation technologies (spinal cord stimulators, deep-brain stimulation systems). The Cardiovascular segment includes coronary disease and aortic valve devices, the WATCHMAN FLX left-atrial appendage closure system, and a suite of implantable cardiac rhythm management products such as CRT-D/CRT-P pacemakers, MRI-compatible sub-cutaneous ICDs, and remote monitoring platforms.

Key performance indicators suggest solid momentum: FY 2023 revenue reached roughly $12.6 billion, with MedSurg contributing about 55% and delivering a 23% operating margin, while Cardiovascular posted a 21% margin. R&D intensity remains near 9% of sales, reflecting continued pipeline investment. Sector-wide drivers-an aging U.S. population, rising prevalence of chronic cardiovascular and gastrointestinal conditions, and a projected 5% CAGR in global healthcare spending-support demand growth for BSX’s high-margin devices.

For a deeper, data-driven assessment of Boston Scientific’s valuation and risk profile, you may find ValueRay’s analytical dashboards useful.

BSX Stock Overview

Market Cap in USD 147,088m
Sub-Industry Health Care Equipment
IPO / Inception 1992-05-18
Return 12m vs S&P 500 -2.76%
Analyst Rating 4.59 of 5

BSX Dividends

Currently no dividends paid

BSX Growth Ratios

Metric Value
CAGR 3y 30.63%
CAGR/Max DD Calmar Ratio 1.97
CAGR/Mean DD Pain Ratio 11.31
Current Volume 13388.5k
Average Volume 7046.5k

Piotroski VR‑10 (Strict, 0-10) 8.5

Net Income (2.79b TTM) > 0 and > 6% of Revenue (6% = 1.16b TTM)
FCFTA 0.09 (>2.0%) and ΔFCFTA 3.51pp (YES ≥ +1.0pp, WARN ≥ +0.5pp)
NWC/Revenue 13.99% (prev 17.92%; Δ -3.93pp) (YES ≤20% & Δ≤-1pp; WARN ≤25% & Δ≤0 oder ≤40% & Δ≤-3pp)
CFO/TA 0.11 (>3.0%) and CFO 4.63b > Net Income 2.79b (YES >=105%, WARN >=100%)
Net Debt (10.20b) to EBITDA (4.68b) ratio: 2.18 <= 3.0 (WARN <= 3.5)
Current Ratio 1.51 (target 1.5–3.0; WARN 1.2–<1.5 or >3.0–5.0; CFO/TA gate active)
Outstanding Shares last Quarter (1.50b) change vs 12m ago 0.54% (target <= -2.0% for YES)
Gross Margin 65.05% (prev 62.41%; Δ 2.64pp) >=18% & Δ>=+0.5pp (WARN >=15% & Δ>=0)
Asset Turnover 47.90% (prev 41.78%; Δ 6.12pp) >=50% & Δ>=+2pp (WARN >=35% & Δ>=0)
Interest Coverage Ratio 6.57 (EBITDA TTM 4.68b / Interest Expense TTM 403.0m) >= 6 (WARN >= 3)

Altman Z'' 1.50

(A) 0.06 = (Total Current Assets 8.04b - Total Current Liabilities 5.33b) / Total Assets 42.71b
(B) 0.11 = Retained Earnings (Balance) 4.90b / Total Assets 42.71b
(C) 0.07 = EBIT TTM 2.65b / Avg Total Assets 40.39b
(D) 0.26 = Book Value of Equity 4.90b / Total Liabilities 19.08b
Total Rating: 1.50 = (6.56 * A) + (3.26 * B) + (6.72 * C) + (1.05 * D)

ValueRay F-Score (Strict, 0-100) 72.74

1. Piotroski 8.50pt
2. FCF Yield 2.36%
3. FCF Margin 19.15%
4. Debt/Equity 0.48
5. Debt/Ebitda 2.18
6. ROIC - WACC (= -1.67)%
7. RoE 12.42%
8. Rev. Trend 98.97%
9. EPS Trend 97.14%

What is the price of BSX shares?

As of November 24, 2025, the stock is trading at USD 96.88 with a total of 13,388,474 shares traded.
Over the past week, the price has changed by -4.80%, over one month by -5.38%, over three months by -7.83% and over the past year by +8.55%.

Is BSX a buy, sell or hold?

Boston Scientific has received a consensus analysts rating of 4.59. Therefore, it is recommended to buy BSX.
  • Strong Buy: 23
  • Buy: 8
  • Hold: 3
  • Sell: 0
  • Strong Sell: 0

What are the forecasts/targets for the BSX price?

Issuer Target Up/Down from current
Wallstreet Target Price 126.5 30.6%
Analysts Target Price 126.5 30.6%
ValueRay Target Price 119.6 23.4%

BSX Fundamental Data Overview November 20, 2025

Market Cap USD = 147.09b (147.09b USD * 1.0 USD.USD)
P/E Trailing = 53.0588
P/E Forward = 29.4118
P/S = 7.6018
P/B = 6.4481
P/EG = 0.9953
Beta = 0.674
Revenue TTM = 19.35b USD
EBIT TTM = 2.65b USD
EBITDA TTM = 4.68b USD
Long Term Debt = 10.99b USD (from longTermDebt, last quarter)
Short Term Debt = 483.0m USD (from shortLongTermDebt, last quarter)
Debt = 11.15b USD (from shortLongTermDebtTotal, last fiscal year)
Net Debt = 10.20b USD (from netDebt column, last quarter)
Enterprise Value = 156.96b USD (147.09b + Debt 11.15b - CCE 1.27b)
Interest Coverage Ratio = 6.57 (Ebit TTM 2.65b / Interest Expense TTM 403.0m)
FCF Yield = 2.36% (FCF TTM 3.71b / Enterprise Value 156.96b)
FCF Margin = 19.15% (FCF TTM 3.71b / Revenue TTM 19.35b)
Net Margin = 14.41% (Net Income TTM 2.79b / Revenue TTM 19.35b)
Gross Margin = 65.05% ((Revenue TTM 19.35b - Cost of Revenue TTM 6.76b) / Revenue TTM)
Gross Margin QoQ = 69.93% (prev 67.65%)
Tobins Q-Ratio = 3.68 (Enterprise Value 156.96b / Total Assets 42.71b)
Interest Expense / Debt = 0.78% (Interest Expense 87.0m / Debt 11.15b)
Taxrate = 19.49% (183.0m / 939.0m)
NOPAT = 2.13b (EBIT 2.65b * (1 - 19.49%))
Current Ratio = 1.51 (Total Current Assets 8.04b / Total Current Liabilities 5.33b)
Debt / Equity = 0.48 (Debt 11.15b / totalStockholderEquity, last quarter 23.39b)
Debt / EBITDA = 2.18 (Net Debt 10.20b / EBITDA 4.68b)
Debt / FCF = 2.75 (Net Debt 10.20b / FCF TTM 3.71b)
Total Stockholder Equity = 22.45b (last 4 quarters mean from totalStockholderEquity)
RoA = 6.53% (Net Income 2.79b / Total Assets 42.71b)
RoE = 12.42% (Net Income TTM 2.79b / Total Stockholder Equity 22.45b)
RoCE = 7.91% (EBIT 2.65b / Capital Employed (Equity 22.45b + L.T.Debt 10.99b))
RoIC = 6.33% (NOPAT 2.13b / Invested Capital 33.63b)
WACC = 8.00% (E(147.09b)/V(158.23b) * Re(8.56%) + D(11.15b)/V(158.23b) * Rd(0.78%) * (1-Tc(0.19)))
Discount Rate = 8.56% (= CAPM, Blume Beta Adj.)
Shares Correlation 3-Years: 100.0 | Cagr: 0.63%
[DCF Debug] Terminal Value 79.78% ; FCFE base≈3.01b ; Y1≈3.71b ; Y5≈6.33b
Fair Price DCF = 65.79 (DCF Value 97.53b / Shares Outstanding 1.48b; 5y FCF grow 25.0% → 3.0% )
EPS Correlation: 97.14 | EPS CAGR: 16.74% | SUE: 2.12 | # QB: 11
Revenue Correlation: 98.97 | Revenue CAGR: 17.61% | SUE: 2.10 | # QB: 8

Additional Sources for BSX Stock

News: Wall Street Journal | Benzinga | Yahoo Finance
Tweets: X | Stocktwits
Fund Manager Positions: Dataroma | Stockcircle